1
|
Kim S, Jee HJ, Park JY, Bae SH, Kim SH, Kim E, Lee S, Jung YS. Hypnotic effect of AR-001 through adenosine A 1 receptor. Eur J Pharmacol 2024; 981:176847. [PMID: 39089463 DOI: 10.1016/j.ejphar.2024.176847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 07/22/2024] [Accepted: 07/24/2024] [Indexed: 08/04/2024]
Abstract
Insomnia is one of the most common sleep disorders, affecting 10-15% of the global population. Because classical remedies used to treat insomnia have various side effects, new therapeutics for insomnia are attracting attention. In the present study, we found that N2-Ethyl-N4-(furan-2-ylmethyl) quinazoline-2,4-diamine (AR-001) has adenosine A1 receptor agonistic activity and exhibits hypnotic efficacy by decreasing sleep onset latency and increasing total sleep time in a pentobarbital-induced sleep model. This hypnotic effect of AR-001 was significantly inhibited by the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). As a result of immunohistochemistry, AR-001 was shown to increase neural activity in the sleep-promoting region, ventrolateral preoptic nucleus (VLPO), and decrease neural activity in the wake-promoting region, basal forebrain (BF), and lateral hypothalamus (LH), and that these effects of AR-001 were significantly inhibited by DPCPX treatment. In addition, AR-001 increased adenosine A1 receptor mRNA levels in the hypothalamus. In conclusion, this study suggests that AR-001 has a hypnotic effect, at least partially, through adenosine A1 receptor and may have therapeutic potential for insomnia.
Collapse
Affiliation(s)
- Suyeon Kim
- Department of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea
| | - Hye Jin Jee
- Department of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea; AI-Super Convergence KIURI Translational Research Center, Ajou University School of Medicine, Suwon, 16499, Republic of Korea; Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, 16499, Republic of Korea
| | - Ju-Young Park
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Republic of Korea
| | - Sung Hun Bae
- AI-Super Convergence KIURI Translational Research Center, Ajou University School of Medicine, Suwon, 16499, Republic of Korea
| | - So Hee Kim
- Department of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea; Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, 16499, Republic of Korea
| | - Eunha Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Republic of Korea; Advanced College of Bio-convergence Engineering, Ajou University, Suwon, 16499, Republic of Korea; Department of Advanced Bio-convergence Engineering, Ajou University, Suwon, 16499, Republic of Korea.
| | - Sunghou Lee
- Department of Green Chemical Engineering, College of Engineering, Sangmyung University, Cheonan, 30116, Republic of Korea.
| | - Yi-Sook Jung
- Department of Pharmacy, Ajou University, Suwon, 16499, Republic of Korea; Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, 16499, Republic of Korea.
| |
Collapse
|
2
|
Wang Y, Huang Y, Li Y, Li K, Luo Z. A TEMPO promoted tandem reaction of 2-aminobenzophenones and benzylamines under electrochemical conditions. Org Biomol Chem 2024; 22:1983-1987. [PMID: 38358360 DOI: 10.1039/d4ob00037d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Abstract
This study describes the efficient synthesis of quinazolines promoted by TEMPO via electro-catalysis with 2-aminobenzophenones and benzylamines. The method exhibited remarkable chemoselectivity under mild reaction conditions. A series of quinazolines could be obtained in moderate to good yields. In addition, control experiments were carried out to verify the reaction mechanism. Furthermore, the synthesis on the gram scale was conducted successfully to give the target product.
Collapse
Affiliation(s)
- Yu Wang
- School of Chemical and Blasting Engineering, Anhui University of Science and Technology, Huainan 232001, China.
| | - Yekai Huang
- School of Chemical and Blasting Engineering, Anhui University of Science and Technology, Huainan 232001, China.
| | - Yanan Li
- School of Chemical and Blasting Engineering, Anhui University of Science and Technology, Huainan 232001, China.
| | - Kuiliang Li
- School of Chemical and Blasting Engineering, Anhui University of Science and Technology, Huainan 232001, China.
| | - Zaigang Luo
- School of Chemical and Blasting Engineering, Anhui University of Science and Technology, Huainan 232001, China.
| |
Collapse
|
3
|
Lopez-Sanchez MA, Del Carmen Garcia-Rodriguez M, Aguayo-Ortiz R, Hernandez-Cruz E, Figueroa-Figueroa DI, Hernandez-Luis F. Synthesis of Quinazolin-2,4,6-triamine Derivatives as Non-purine Xanthine Oxidase Inhibitors and Exploration of Their Toxicological Potential. ChemMedChem 2023; 18:e202300184. [PMID: 37642254 DOI: 10.1002/cmdc.202300184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2023] [Revised: 08/02/2023] [Indexed: 08/31/2023]
Abstract
In this work, a new set of quinazolin-2,4,6-triamine derivatives were synthesized to explore their potential biological activity as xanthine oxidase (XO) inhibitors, superoxide scavengers and screening of their toxicological profile. Among all the synthesized compounds, B1 exhibited better inhibitory activity against bovine xanthine oxidase (bXO) than allopurinol (IC50 =1.56 μM and IC50 =6.99 μM, respectively). As superoxide scavengers, B1, B2 and B13 exhibited a better effect than allopurinol (97.3 %, 82.1 %, 87.4 % and 69.4 %, respectively). Regarding the toxicological profile, B1 was less cytotoxic than methotrexate on HCT-15 cancer cells. Apoptosis results obtained in cells of female and male mice, showed that B1 and B2 presented a similar behaviour to CrO3 (positive control) with respect to the average frequency to induce apoptosis; while B13 apoptosis induced effect was similar to DMSO and control group. Finally, B1, B2, B13 did not induce genotoxicity in a micronuclei murine model compared to CrO3 .
Collapse
Affiliation(s)
- Marcela A Lopez-Sanchez
- Departamento de Farmacia, Facultad de Química, UNAM, Universidad 3000, 04510, Ciudad de México, México
| | - María Del Carmen Garcia-Rodriguez
- Laboratorio de Antimutagénesis, Anticarcinogénesis y Antiteratogénesis Ambiental, Facultad de Estudios Superiores-Zaragoza, UNAM, Av Guelatao 66, 09230, Ciudad de México, México
| | - Rodrigo Aguayo-Ortiz
- Departamento de Farmacia, Facultad de Química, UNAM, Universidad 3000, 04510, Ciudad de México, México
| | - Estefani Hernandez-Cruz
- Laboratorio de Antimutagénesis, Anticarcinogénesis y Antiteratogénesis Ambiental, Facultad de Estudios Superiores-Zaragoza, UNAM, Av Guelatao 66, 09230, Ciudad de México, México
| | - Diego I Figueroa-Figueroa
- Departamento de Farmacia, Facultad de Química, UNAM, Universidad 3000, 04510, Ciudad de México, México
| | - Francisco Hernandez-Luis
- Departamento de Farmacia, Facultad de Química, UNAM, Universidad 3000, 04510, Ciudad de México, México
| |
Collapse
|
4
|
Kumari A, Jaiswal T, Kumar V, Hura N, Kumar G, Babu NK, Acharya A, Roy PK, Guchhait SK, Singh S. Identification of 2-arylquinazolines with alkyl-polyamine motifs as potent antileishmanial agents: synthesis and biological evaluation studies. RSC Med Chem 2022; 13:320-326. [PMID: 35434631 PMCID: PMC8942235 DOI: 10.1039/d1md00336d] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2021] [Accepted: 01/04/2022] [Indexed: 11/19/2023] Open
Abstract
2-Arylquinazolines with a range of alkyl polyamines as side chain/ring functional motifs at the 4th-position were considered for antileishmanial study with the rationale that related heterocyclic scaffolds and polyamine functionalities are present in drugs, clinical trial agents, natural products and anti-parasitic/leishmanial agents. Synthesis involves construction of the 2-arylquinazolin-4-one ring and deoxyamination via deoxychlorination followed by SNAr-based amination or a methodology of SNAr-deoxyamination driven by BOP-mediated hydroxyl-activation. Various alkyl-polyamines important for activities were incorporated. A total of 26 compounds were prepared and screened against Leishmania donovani (Ld) promastigote cells using the MTT assay. Most of the investigated series of compounds showed characteristic leishmanicidal properties. Several compounds showed pronounced leishmanicidal activities (IC50: 5-6.5 μM) with higher efficiency than the antileishmanial drug miltefosine (IC50: 10.5 μM), and relatively less cytotoxicity to macrophage host cells (SI: 9.27-13.5) compared to miltefosine (SI: 3.42). Important pharmacophoric skeletons were identified.
Collapse
Affiliation(s)
- Anjila Kumari
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Tara Jaiswal
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Vinay Kumar
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Neha Hura
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Gulshan Kumar
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Neerupudi Kishore Babu
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Ayan Acharya
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Pradyot K Roy
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Sankar K Guchhait
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| | - Sushma Singh
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research S.A.S. Nagar 160062 India
| |
Collapse
|
5
|
Zuo B, Shao H, Zheng Y, Ma Y, Li W, Huang M, Deng Q. The Core‐Shell Magnetic Mesoporous Microspheres Immobilized NHC‐Palladacycles: An Efficient and Recyclable Catalyst for Suzuki–Miyaura Cross‐Coupling of Pharmaceutical Synthesis. ASIAN J ORG CHEM 2022. [DOI: 10.1002/ajoc.202200018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Bin Zuo
- University of Shanghai for Science and Technology School of Materials and Chemistry No. 334 Jungong Road, Shanghai, 200093, P.R. China 200093 Shanghai CHINA
| | - Han Shao
- University of Shanghai for Science and Technology School of Materials and Chemistry Shanghai 200093, China. Shanghai CHINA
| | - Yan Zheng
- University of Shanghai for Science and Technology School of Materials and Chemistry Shanghai 200093, China. Shanghai CHINA
| | - Yunhua Ma
- University of Shanghai for Science and Technology School of Materials and Chemistry Shanghai 200093, China. Shanghai CHINA
| | - Wanfang Li
- University of Shanghai for Science and Technology School of Materials and Chemistry Shanghai 200093, China. Shanghai CHINA
| | - Mingxian Huang
- University of Shanghai for Science and Technology School of Materials and Chemistry Shanghai 200093, China. Shanghai CHINA
| | - Qinyue Deng
- University of Shanghai for Science and Technology School of Materials and Chemistry No. 334 Jungong Road 200093 Shanghai CHINA
| |
Collapse
|
6
|
Barbosa da Silva E, Rocha DA, Fortes IS, Yang W, Monti L, Siqueira-Neto JL, Caffrey CR, McKerrow J, Andrade SF, Ferreira RS. Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors. J Med Chem 2021; 64:13054-13071. [PMID: 34461718 DOI: 10.1021/acs.jmedchem.1c01151] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The cysteine proteases, cruzain and TbrCATL (rhodesain), are therapeutic targets for Chagas disease and Human African Trypanosomiasis, respectively. Among the known inhibitors for these proteases, we have described N4-benzyl-N2-phenylquinazoline-2,4-diamine (compound 7 in the original publication, 1a in this study), as a competitive cruzain inhibitor (Ki = 1.4 μM). Here, we describe the synthesis and biological evaluation of 22 analogs of 1a, containing modifications in the quinazoline core, and in the substituents in positions 2 and 4 of this ring. The analogs demonstrate low micromolar inhibition of the target proteases and cidal activity against Trypanosoma cruzi with up to two log selectivity indices in counterscreens with myoblasts. Fourteen compounds were active against Trypanosoma brucei at low to mid micromolar concentrations. During the optimization of 1a, structure-based design and prediction of physicochemical properties were employed to maintain potency against the enzymes while removing colloidal aggregator characteristics observed for some molecules in this series.
Collapse
Affiliation(s)
- Elany Barbosa da Silva
- Biochemistry and Immunology Department, Biological Sciences Institute, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais 31270-901, Brazil.,Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0657, United States
| | - Débora A Rocha
- Pharmaceutical Synthesis Group (PHARSG), Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90040-060, Brazil.,Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90040-060, Brazil
| | - Isadora S Fortes
- Pharmaceutical Synthesis Group (PHARSG), Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90040-060, Brazil.,Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90040-060, Brazil
| | - Wenqian Yang
- Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0657, United States
| | - Ludovica Monti
- Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0657, United States
| | - Jair L Siqueira-Neto
- Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0657, United States
| | - Conor R Caffrey
- Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0657, United States
| | - James McKerrow
- Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0657, United States
| | - Saulo F Andrade
- Pharmaceutical Synthesis Group (PHARSG), Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90040-060, Brazil.,Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90040-060, Brazil.,Graduate Program in Agricultural and Environmental Microbiology, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90040-060, Brazil
| | - Rafaela S Ferreira
- Biochemistry and Immunology Department, Biological Sciences Institute, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais 31270-901, Brazil
| |
Collapse
|
7
|
Abdelhameed A, Feng M, Joice AC, Zywot EM, Jin Y, La Rosa C, Liao X, Meeds HL, Kim Y, Li J, McElroy CA, Wang MZ, Werbovetz KA. Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker. ACS Infect Dis 2021; 7:1901-1922. [PMID: 33538576 DOI: 10.1021/acsinfecdis.0c00855] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Due to the limitations of existing medications, there is a critical need for new drugs to treat visceral leishmaniasis. Since arylimidamides and antifungal azoles both show oral activity in murine visceral leishmaniasis models, a molecular hybridization approach was employed where arylimidamide and azole groups were separated by phenoxyalkyl linkers in an attempt to capitalize on the favorable antileishmanial properties of both series. Among the target compounds synthesized, a greater antileishmanial potency against intracellular Leishmania donovani was observed as the linker length increased from two to eight carbons and when an imidazole ring was employed as the terminal group compared to a 1,2,4-triazole group. Compound 24c (N-(4-((8-(1H-imidazol-1-yl)octyl)oxy)-2-isopropoxyphenyl) picolinimidamide) displayed activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM. When tested in a murine visceral leishmaniasis model, compound 24c at a dose of 75 mg/kg/day p.o. for five consecutive days resulted in a modest 33% decrease in liver parasitemia compared to the control group, indicating that further optimization of these molecules is needed. While potent hybrid compounds bearing an imidazole terminal group were also strong inhibitors of recombinant CYP51 from L. donovani, as assessed by a fluorescence-based assay, additional targets are likely to play an important role in the antileishmanial action of these compounds.
Collapse
Affiliation(s)
- Ahmed Abdelhameed
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt
| | - Mei Feng
- Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047, United States
| | - April C. Joice
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Emilia M. Zywot
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Yiru Jin
- Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047, United States
| | - Chris La Rosa
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Xiaoping Liao
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Heidi L. Meeds
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Yena Kim
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Junan Li
- College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Craig A. McElroy
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Michael Zhuo Wang
- Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas 66047, United States
| | - Karl A. Werbovetz
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| |
Collapse
|
8
|
Bao Z, Zhou ZY, Mao YT, Shao LX. N-heterocyclic carbene-Pd(II)-1-methylimidazole complex-catalyzed Suzuki-Miyaura coupling of 2-chloro-4-aminoquinazolines with arylboronic acids. Tetrahedron 2020. [DOI: 10.1016/j.tet.2020.131548] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Moghadam ES, Tehrani MH, Csuk R, Fischer L, Faramarzi MA, Rashidi A, Javadi I, Amini M. 2,4-Disubstituted Quinazoline Derivatives Act as Inducers of Tubulin Polymerization: Synthesis and Cytotoxicity. Anticancer Agents Med Chem 2020; 19:1048-1057. [PMID: 30868963 DOI: 10.2174/1871520619666190314125254] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 03/04/2019] [Accepted: 03/05/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND During last recent years number of anti-tubulin agents were introduced for treatment of diverse kind of cancer. Despite of their potential in treatment of cancer, drug resistance and adverse toxicity such as peripheral neuropathy are some of the negative criteria of anti-tubulin agents. METHODS Twenty seven quinazoline derivatives were synthesized using a multicomponent reaction. The cytotoxicity of compounds 1-27 was tested in SRB assays employing five different human tumor cell lines. Effect of two of active compounds on tubulin polymerization was also checked using a commercially available assay kit. Molecular modelling studies were also performed using autodock tools software. RESULTS SRB assays showed that compounds 2, 9, 16 and 26, being highly cytotoxic with IC50 values ranging between 2.1 and 14.3µM. The possible mode of action of compounds, 2, 9, 16 and 26, and the taxol binding site of the protein tubulin, an important goal for antimitotic drugs, was also studied by molecular docking, which showed reasonable interactions with tubulin active site, followed by investigation of the effects of compounds 9 and 16 on the polymerization of tubulin. The results showed the tested compounds to be highly active as inducers of tubulin polymerization. CONCLUSION Altogether, with respect to obtained results, it is attractive and beneficial to further investigation on quinazoline scaffold as antimitotic agents.
Collapse
Affiliation(s)
- Ebrahim S Moghadam
- Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran
| | - Maryam H Tehrani
- Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran
| | - René Csuk
- Martin-Luther-University Halle-Wittenberg, Organic Chemistry, Kurt-Mothes-Str. 2, D-06120 Halle (Saale), Germany
| | - Lucie Fischer
- Martin-Luther-University Halle-Wittenberg, Organic Chemistry, Kurt-Mothes-Str. 2, D-06120 Halle (Saale), Germany
| | - Mohammad Ali Faramarzi
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Arezoo Rashidi
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran.,Department of Toxicology, Faculty of Pharmacy, Shahreza Branch, Islamic Azad University, Shahreza, Iran
| | - Iraj Javadi
- Department of Toxicology, Faculty of Pharmacy, Shahreza Branch, Islamic Azad University, Shahreza, Iran
| | - Mohsen Amini
- Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran
| |
Collapse
|
10
|
Auti PS, George G, Paul AT. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC Adv 2020; 10:41353-41392. [PMID: 35516563 PMCID: PMC9057921 DOI: 10.1039/d0ra06642g] [Citation(s) in RCA: 102] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 10/27/2020] [Indexed: 12/18/2022] Open
Abstract
Due to the pharmacological activities of quinazoline and quinazolinone scaffolds, it has aroused great interest in medicinal chemists for the development of new drugs or drug candidates. The pharmacological activities of quinazoline and its related scaffolds include anti-cancer, anti-microbial, anti-convulsant, and antihyperlipidaemia. Recently, molecular hybridization technology is used for the development of hybrid analogues with improved potency by combining two or more pharmacophores of bioactive scaffolds. The molecular hybridization of various biologically active pharmacophores with quinazoline derivatives resulted in lead compounds with multi-faceted biological activity wherein specific as well as multiple targets were involved. The present review summarizes the advances in lead compounds of quinazoline hybrids and their related heterocycles in medicinal chemistry. Moreover, the review also helps to intensify the drug development process by providing an understanding of the potential role of these hybridized pharmacophoric features in exhibiting various pharmacological activities. Recent advances in quinazoline/quinazolinone hybrid heterocycles in medicinal chemistry and their pharmacological diversification.![]()
Collapse
Affiliation(s)
- Prashant S. Auti
- Laboratory of Natural Product Chemistry
- Department of Pharmacy
- Birla Institute of Technology and Science, Pilani (BITS Pilani)
- Pilani Campus
- India
| | - Ginson George
- Laboratory of Natural Product Chemistry
- Department of Pharmacy
- Birla Institute of Technology and Science, Pilani (BITS Pilani)
- Pilani Campus
- India
| | - Atish T. Paul
- Laboratory of Natural Product Chemistry
- Department of Pharmacy
- Birla Institute of Technology and Science, Pilani (BITS Pilani)
- Pilani Campus
- India
| |
Collapse
|
11
|
Abdelhameed A, Liao X, McElroy CA, Joice AC, Rakotondraibe L, Li J, Slebodnick C, Guo P, Wilson WD, Werbovetz KA. Synthesis and antileishmanial evaluation of thiazole orange analogs. Bioorg Med Chem Lett 2020; 30:126725. [DOI: 10.1016/j.bmcl.2019.126725] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 09/26/2019] [Accepted: 09/28/2019] [Indexed: 01/10/2023]
|
12
|
Corman HN, Shoue DA, Norris-Mullins B, Melancon BJ, Morales MA, McDowell MA. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds. Int J Antimicrob Agents 2019; 54:496-501. [PMID: 31323307 DOI: 10.1016/j.ijantimicag.2019.07.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 06/28/2019] [Accepted: 07/10/2019] [Indexed: 12/22/2022]
Abstract
Leishmania parasites are the causative agents of a wide spectrum of human diseases. The clinical manifestations of leishmaniasis range from self-healing skin lesions to fatality. The World Health Organization has classed leishmaniasis as a category 1 neglected tropical disease. Leishmaniasis represents a major international health challenge, affecting 12 million people per year and with nearly 310 million people at risk. The first-line chemotherapies used to treat leishmaniasis are intravenous pentavalent antimonials; however, these drugs are highly toxic. As the use of oral treatment options such as paromomycin and miltefosine has increased, the incidence of disease relapse has increased and drug resistance to antimonials has developed, emphasizing the importance of identifying new chemotherapies. A novel, target-free fluorometric high-throughput screen with an average Z-score of 0.73 +/- 0.13 has been developed to identify small molecules with antileishmanial activity. Screening of 10,000 small molecules from the ChemBridge DIVER-set™ library cassette #5 yielded 210 compounds that killed 80% of parasites, resulting in a hit rate of 2.1%. One hundred and nine molecular scaffolds were represented within the hit compounds, and one scaffold that exhibited potent antileishmanial activity was 2,4-diaminoquinazoline. Host cell toxicity was determined prior to in-vitro infection of human THP-1 macrophages with Leishmania donovani mCherry expressing promastigotes; successful drug treatment was considered when the half maximal inhibitory concentration was <10 µM. BALB/c mice were infected with Leishmania major mCherry promastigotes and treated with small molecules that were successful during in-vitro infections. Several small molecules tested were as efficacious at resolving cutaneous leishmaniasis lesions in mice as known antimonial treatments.
Collapse
Affiliation(s)
- Hannah N Corman
- Eck Institute for Global Health, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA; Warren Family Center for Drug Discovery and Development, University of Notre Dame, Notre Dame, IN, USA
| | - Douglas A Shoue
- Eck Institute for Global Health, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA; Warren Family Center for Drug Discovery and Development, University of Notre Dame, Notre Dame, IN, USA
| | - Brianna Norris-Mullins
- Eck Institute for Global Health, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA
| | - Bruce J Melancon
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA; Warren Family Center for Drug Discovery and Development, University of Notre Dame, Notre Dame, IN, USA
| | - Miguel A Morales
- Eck Institute for Global Health, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
| | - Mary Ann McDowell
- Eck Institute for Global Health, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA; Warren Family Center for Drug Discovery and Development, University of Notre Dame, Notre Dame, IN, USA.
| |
Collapse
|
13
|
Pobsuk N, Paracha TU, Chaichamnong N, Salaloy N, Suphakun P, Hannongbua S, Choowongkomon K, Pekthong D, Chootip K, Ingkaninan K, Gleeson MP. Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5. Bioorg Med Chem Lett 2019; 29:267-270. [DOI: 10.1016/j.bmcl.2018.11.043] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 10/19/2018] [Accepted: 11/20/2018] [Indexed: 12/23/2022]
|
14
|
An overview of quinazolines: Pharmacological significance and recent developments. Eur J Med Chem 2018; 151:628-685. [DOI: 10.1016/j.ejmech.2018.03.076] [Citation(s) in RCA: 107] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 03/18/2018] [Accepted: 03/26/2018] [Indexed: 12/19/2022]
|
15
|
Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations. Antimicrob Agents Chemother 2017; 62:AAC.01129-17. [PMID: 29061761 DOI: 10.1128/aac.01129-17] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 10/18/2017] [Indexed: 01/04/2023] Open
Abstract
Given the limitations of current antileishmanial drugs and the utility of oral combination therapy for other infections, developing an oral combination against visceral leishmaniasis should be a high priority. In vitro combination studies with DB766 and antifungal azoles against intracellular Leishmania donovani showed that posaconazole and ketoconazole, but not fluconazole, enhanced DB766 potency. Pharmacokinetic analysis of DB766-azole combinations in uninfected Swiss Webster mice revealed that DB766 exposure was increased by higher posaconazole and ketoconazole doses, while DB766 decreased ketoconazole exposure. In L. donovani-infected BALB/c mice, DB766-posaconazole combinations given orally for 5 days were more effective than DB766 or posaconazole alone. For example, 81% ± 1% (means ± standard errors) inhibition of liver parasite burden was observed for 37.5 mg/kg of body weight DB766 plus 15 mg/kg posaconazole, while 37.5 mg/kg DB766 and 15 mg/kg posaconazole administered as monotherapy gave 40% ± 5% and 21% ± 3% inhibition, respectively. Combination index (CI) analysis indicated that synergy or moderate synergy was observed in six of nine combined dose groups, while the other three were nearly additive. Liver concentrations of DB766 and posaconazole increased in almost all combination groups compared to monotherapy groups, although many increases were not statistically significant. For DB766-ketoconazole combinations evaluated in this model, two were antagonistic, one displayed synergy, and one was nearly additive. These data indicate that the efficacy of DB766-posaconazole and DB766-ketoconazole combinations in vivo is influenced in part by the pharmacokinetics of the combination, and that the former combination deserves further consideration in developing new treatment strategies against visceral leishmaniasis.
Collapse
|
16
|
Ortiz D, Guiguemde WA, Hammill JT, Carrillo AK, Chen Y, Connelly M, Stalheim K, Elya C, Johnson A, Min J, Shelat A, Smithson DC, Yang L, Zhu F, Guy RK, Landfear SM. Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. PLoS Negl Trop Dis 2017; 11:e0006157. [PMID: 29287089 PMCID: PMC5764437 DOI: 10.1371/journal.pntd.0006157] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Revised: 01/11/2018] [Accepted: 12/09/2017] [Indexed: 12/20/2022] Open
Abstract
Leishmaniasis is a parasitic infection that afflicts approximately 12 million people worldwide. There are several limitations to the approved drug therapies for leishmaniasis, including moderate to severe toxicity, growing drug resistance, and the need for extended dosing. Moreover, miltefosine is currently the only orally available drug therapy for this infection. We addressed the pressing need for new therapies by pursuing a two-step phenotypic screen to discover novel, potent, and orally bioavailable antileishmanials. First, we conducted a high-throughput screen (HTS) of roughly 600,000 small molecules for growth inhibition against the promastigote form of the parasite life cycle using the nucleic acid binding dye SYBR Green I. This screen identified approximately 2,700 compounds that inhibited growth by over 65% at a single point concentration of 10 μM. We next used this 2700 compound focused library to identify compounds that were highly potent against the disease-causing intra-macrophage amastigote form and exhibited limited toxicity toward the host macrophages. This two-step screening strategy uncovered nine unique chemical scaffolds within our collection, including two previously described antileishmanials. We further profiled two of the novel compounds for in vitro absorption, distribution, metabolism, excretion, and in vivo pharmacokinetics. Both compounds proved orally bioavailable, affording plasma exposures above the half-maximal effective concentration (EC50) concentration for at least 12 hours. Both compounds were efficacious when administered orally in a murine model of cutaneous leishmaniasis. One of the two compounds exerted potent activity against trypanosomes, which are kinetoplastid parasites related to Leishmania species. Therefore, this compound could help control multiple parasitic diseases. The promising pharmacokinetic profile and significant in vivo efficacy observed from our HTS hits highlight the utility of our two-step phenotypic screening strategy and strongly suggest that medicinal chemistry optimization of these newly identified scaffolds will lead to promising candidates for an orally available anti-parasitic drug.
Collapse
Affiliation(s)
- Diana Ortiz
- Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon, United States of America
| | - W. Armand Guiguemde
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Jared T. Hammill
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Angela K. Carrillo
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Yizhe Chen
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Michele Connelly
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Kayla Stalheim
- Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon, United States of America
| | - Carolyn Elya
- Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon, United States of America
| | - Alex Johnson
- Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon, United States of America
| | - Jaeki Min
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Anang Shelat
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - David C. Smithson
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Lei Yang
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Fangyi Zhu
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - R. Kiplin Guy
- Department of Chemical Biology and Theraputics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
| | - Scott M. Landfear
- Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon, United States of America
| |
Collapse
|
17
|
Yang L, Ge S, Huang J, Bao X. Synthesis of novel (E)-2-(4-(1H-1,2,4-triazol-1-yl)styryl)-4- (alkyl/arylmethyleneoxy)quinazoline derivatives as antimicrobial agents. Mol Divers 2017; 22:71-82. [PMID: 29119421 DOI: 10.1007/s11030-017-9792-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Accepted: 10/23/2017] [Indexed: 10/18/2022]
Abstract
A series of novel (E)-2-(4-(1H-1,2,4-triazol-1-yl)styryl)-4-(alkyl/arylmethyleneoxy)quinazoline derivatives (4a-4s) were synthesized in good to excellent yields, and their structures were fully characterized by [Formula: see text] NMR, [Formula: see text] NMR, HRMS and IR spectra. The structure of compound 4b was further confirmed via single-crystal X-ray diffraction analysis. The bioassay results indicated that compounds 4s, 4q and 4n inhibit phytopathogenic bacterium Xanthomonas axonopodis pv. citri (Xac) more potently than commercial bactericide bismerthiazol. However, not a single compound can effectively inhibit three pathogenic fungi tested at 50 [Formula: see text].
Collapse
Affiliation(s)
- Lan Yang
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Centre for Research and Development of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Shijia Ge
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Centre for Research and Development of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Jian Huang
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Centre for Research and Development of Fine Chemicals, Guizhou University, Guiyang, 550025, China
| | - Xiaoping Bao
- State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Centre for Research and Development of Fine Chemicals, Guizhou University, Guiyang, 550025, China.
| |
Collapse
|
18
|
Characterizing the Antimicrobial Activity of N2, N4-Disubstituted Quinazoline-2,4-Diamines toward Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2017; 61:AAC.00059-17. [PMID: 28289036 DOI: 10.1128/aac.00059-17] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 03/06/2017] [Indexed: 01/12/2023] Open
Abstract
We previously reported a series of N2,N4-disubstituted quinazoline-2,4-diamines as dihydrofolate reductase inhibitors with potent in vitro and in vivo antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains. In this work, we extended our previous study to the Gram-negative pathogen Acinetobacter baumannii We determined that optimized N2,N4-disubstituted quinazoline-2,4-diamines are strongly antibacterial against multidrug-resistant A. baumannii strains when the 6-position is replaced with a halide or an alkyl substituent. Such agents display potent antibacterial activity, with MICs as low as 0.5 μM, while proving to be strongly bactericidal. Interestingly, these compounds also possess the potential for antibiofilm activity, eradicating 90% of cells within a biofilm at or near MICs. Using serial passage assays, we observed a limited capacity for the development of resistance toward these molecules (4-fold increase in MIC) compared to existing folic acid synthesis inhibitors, such as trimethoprim (64-fold increase) and sulfamethoxazole (128-fold increase). We also identified limited toxicity toward human cells, with 50% lethal doses (LD50s) of ≤23 μM for lead agents 4 and 5. Finally, we demonstrated that our lead agents have excellent in vivo efficacy, with lead agent 5 proving more efficacious than tigecycline in a murine model of A. baumannii infection (90% survival versus 66%), despite being used at a lower dose (2 versus 30 mg kg-1). Together, our results demonstrate that N2,N4-disubstituted quinazoline-2,4-diamines have strong antimicrobial and antibiofilm activities against both Gram-positive organisms and Gram-negative pathogens, suggesting strong potential for their development as antibacterial agents.
Collapse
|
19
|
Jiang Z, Hong WD, Cui X, Gao H, Wu P, Chen Y, Shen D, Yang Y, Zhang B, Taylor MJ, Ward SA, O'Neill PM, Zhao S, Zhang K. Synthesis and structure–activity relationship of N4-benzylamine-N2-isopropyl-quinazoline-2,4-diamines derivatives as potential antibacterial agents. RSC Adv 2017. [DOI: 10.1039/c7ra10352b] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
This paper investigated the SAR of the N4-benzylamine-N2-isopropyl-quinazoline-2,4-diamines derivatives with heterocyclic scaffold which showed good activities against S. aureus, E. coli, MRSA, S. epidermidis and S. typhimurium.
Collapse
|
20
|
Zhu X, Farahat AA, Mattamana M, Joice A, Pandharkar T, Holt E, Banerjee M, Gragg JL, Hu L, Kumar A, Yang S, Wang MZ, Boykin DW, Werbovetz KA. Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents. Bioorg Med Chem Lett 2016; 26:2551-2556. [PMID: 27048943 PMCID: PMC4841789 DOI: 10.1016/j.bmcl.2016.03.082] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 03/22/2016] [Accepted: 03/24/2016] [Indexed: 11/28/2022]
Abstract
Arylimidamide (AIA) compounds containing two pyridylimidamide terminal groups (bis-AIAs) possess outstanding in vitro antileishmanial activity, and the frontrunner bis-AIA DB766 (2,5-bis[2-(2-isopropoxy)-4-(2-pyridylimino)aminophenyl]furan) is active in visceral leishmaniasis models when given orally. Eighteen compounds containing a single pyridylimidamide terminal group (mono-AIAs) were synthesized and evaluated for their antileishmanial potential. Six of these compounds exhibited sub-micromolar potency against both intracellular Leishmania donovani and Leishmania amazonensis amastigotes, and three of these compounds also displayed selectivity indexes of 25 or greater for the parasites compared to a J774 macrophage cell line. When given orally at a dose of 100 mg/kg/day for five days, compound 1b (N-(3-isopropoxy-4-(5-phenylfuran-2-yl)phenyl)picolinimidamide methanesulfonate) reduced liver parasitemia by 46% in L. donovani-infected mice. Mono-AIAs are thus a new class of candidate molecules for antileishmanial drug development.
Collapse
Affiliation(s)
- Xiaohua Zhu
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Abdelbasset A Farahat
- Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
| | - Meena Mattamana
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - April Joice
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Trupti Pandharkar
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Elizabeth Holt
- Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA
| | - Moloy Banerjee
- Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA
| | - Jamie L Gragg
- Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA
| | - Laixing Hu
- Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Arvind Kumar
- Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA
| | - Sihyung Yang
- Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS 66047, USA
| | - Michael Zhuo Wang
- Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS 66047, USA
| | - David W Boykin
- Department of Chemistry, Georgia State University, Atlanta, GA 30302, USA
| | - Karl A Werbovetz
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
| |
Collapse
|
21
|
Mowbray CE, Braillard S, Speed W, Glossop PA, Whitlock GA, Gibson KR, Mills JEJ, Brown AD, Gardner JMF, Cao Y, Hua W, Morgans GL, Feijens PB, Matheeussen A, Maes LJ. Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity. J Med Chem 2015; 58:9615-24. [PMID: 26571076 DOI: 10.1021/acs.jmedchem.5b01456] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Visceral leishmaniasis is a severe parasitic disease that is one of the most neglected tropical diseases. Treatment options are limited, and there is an urgent need for new therapeutic agents. Following an HTS campaign and hit optimization, a novel series of amino-pyrazole ureas has been identified with potent in vitro antileishmanial activity. Furthermore, compound 26 shows high levels of in vivo efficacy (>90%) against Leishmania infantum, thus demonstrating proof of concept for this series.
Collapse
Affiliation(s)
- Charles E Mowbray
- Drugs for Neglected Diseases initiative (DNDi) , 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland
| | - Stéphanie Braillard
- Drugs for Neglected Diseases initiative (DNDi) , 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland
| | - William Speed
- Drugs for Neglected Diseases initiative (DNDi) , 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland
| | - Paul A Glossop
- Sandexis Medicinal Chemistry Ltd., Innovation House , Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9ND, United Kingdom
| | - Gavin A Whitlock
- Sandexis Medicinal Chemistry Ltd., Innovation House , Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9ND, United Kingdom
| | - Karl R Gibson
- Sandexis Medicinal Chemistry Ltd., Innovation House , Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9ND, United Kingdom
| | - James E J Mills
- Sandexis Medicinal Chemistry Ltd., Innovation House , Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9ND, United Kingdom
| | - Alan D Brown
- Pfizer Worldwide Medicinal Chemistry , The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, United Kingdom
| | - J Mark F Gardner
- AMG Consultants Ltd., Discovery Park House , Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9ND, United Kingdom
| | - Yafeng Cao
- WuXi AppTec (Wuhan) Company Ltd. , 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People's Republic of China
| | - Wen Hua
- WuXi AppTec (Wuhan) Company Ltd. , 666 Gaoxin Road, East Lake High-Tech Development Zone, Wuhan 430075, People's Republic of China
| | - Garreth L Morgans
- iThemba Pharmaceuticals , Building T5, Pinelands Site, High Street, Modderfontein 1609, Gauteng, South Africa
| | - Pim-Bart Feijens
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp , S7, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium
| | - An Matheeussen
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp , S7, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium
| | - Louis J Maes
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp , S7, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium
| |
Collapse
|